Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
17 studies found for:    SCH-727965 OR dinaciclib
Show Display Options
Rank Status Study
1 Completed A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Dinaciclib;   Biological: Rituximab
2 Active, not recruiting Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Conditions: Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unresectable Pancreatic Carcinoma
Interventions: Drug: Akt Inhibitor MK2206;   Drug: Dinaciclib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
3 Active, not recruiting Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Dinaciclib;   Drug: Epirubicin Hydrochloride;   Other: Laboratory Biomarker Analysis
4 Active, not recruiting Phase 1b Dose De-escalation Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer
Conditions: Advanced or Metastatic Breast Cancer;   Triple Negative Breast Cancer
Intervention: Drug: Dinaciclib & pembrolizumab treatment
5 Terminated
Has Results
Dinaciclib in Treating Patients With Stage III-IV Melanoma
Conditions: Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: dinaciclib;   Other: pharmacological study;   Other: laboratory biomarker analysis
6 Recruiting Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Solid Neoplasm
Interventions: Drug: Dinaciclib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Veliparib
7 Recruiting Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155)
Conditions: rrCLL;   rrMM;   rrDLBCL
Interventions: Biological: pembrolizumab;   Drug: dinaciclib
8 Suspended Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Condition: Recurrent Plasma Cell Myeloma
Interventions: Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Dinaciclib;   Other: Laboratory Biomarker Analysis
9 Active, not recruiting
Has Results
Dinaciclib in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Melanoma;   Lentigo Maligna Melanoma;   Mucosal Melanoma;   Nodular Melanoma;   Recurrent Melanoma;   Stage IV Skin Melanoma;   Superficial Spreading Melanoma
Intervention: Drug: Dinaciclib
10 Terminated SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)
Conditions: Leukemia, Myeloid, Acute;   Lymphoblastic Leukemia, Acute
Interventions: Drug: SCH 727965;   Drug: Gemtuzumab ozogamicin
11 Completed A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)
Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: Dinaciclib;   Drug: Ofatumumab
12 Completed Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)
Conditions: Solid Tumors;   Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Leukemia, Lymphocytic, Chronic. B-Cell
Intervention: Drug: SCH 727965
13 Active, not recruiting Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: Dinaciclib;   Other: Laboratory Biomarker Analysis;   Biological: Ofatumumab;   Other: Pharmacological Study
14 Completed
Has Results
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Refractory Multiple Myeloma
Interventions: Drug: dinaciclib;   Other: laboratory biomarker analysis
15 Terminated SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Conditions: Lymphoma, Mantle-Cell;   Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: SCH 727965;   Drug: Bortezomib;   Biological: Alemtuzumab
16 Completed Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
Conditions: Solid Tumors;   Lymphoma, Non-Hodgkin;   Multiple Myeloma
Interventions: Drug: SCH 727965;   Drug: Aprepitant;   Drug: Ondansetron;   Drug: Dexamethasone
17 Completed SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)
Conditions: Breast Neoplasms;   Carcinoma, Non-Small-Cell Lung
Interventions: Drug: SCH 727965;   Drug: Capecitabine;   Drug: Erlotinib

Study has passed its completion date and status has not been verified in more than two years.